Semin Respir Crit Care Med 2007; 28(3): 303-311
DOI: 10.1055/s-2007-981651
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

How Can We Prevent Multisystem Complications of Cystic Fibrosis?

J. Stuart Elborn1 , 2
  • 1Respiratory Medicine Group, QUB, Northern Ireland
  • 2Northern Ireland Adult Cystic Fibrosis Centre, BCH, Northern Ireland
Further Information

Publication History

Publication Date:
22 August 2007 (online)

ABSTRACT

Cystic fibrosis (CF) is a multisystem disease. Some of this is accounted for by CF transmembrane regulator (CFTR) dysfunction in individual organs but in some cases this is compounded by the effects of systemic inflammation. The inflammation is in response to the chronic infection in the airways and is particularly important as a contributor to CF-related bone disease, CF-related diabetes mellitus, CF-related arthropathy, and vasculitis. Preventing these multisystem complications is difficult. Aggressive specific therapies to treat complications is critically important to maintain nutrition, stop the damaging effects of diabetes, and improve bone mineral density. Aggressive treatment of lung disease to reduce systemic inflammation is likely to be of benefit in preventing the development of CF- related bone disease and may be beneficial in at least delaying the onset of CF-related diabetes. Aggressive treatment of pulmonary infection and inflammation in conjunction with holistic management plans to treat specific organ diseases is an important strategy in improving morbidity and reducing mortality in people with CF.

REFERENCES

  • 1 Chimiel J F, Konston M W. Inflammation and anti-inflammatory therapies for cystic fibrosis.  Clin Chest Med. 2007;  28 331-346
  • 2 Gibson R L, Burns J, Ramsey B W. Pathophysiology and management of pulmonary infections in cystic fibrosis.  Am J Respir Crit Care Med. 2003;  168 918-951
  • 3 UK Cystic Fibrosis Trust Nutrition Working Group .Nutritional Management of Cystic Fibrosis. Bromley, Kent: Cystic Fibrosis Trust 2002
  • 4 Lindley K J. Pancreatic involvement: clinical manifestations, pathophysiology and new treatments. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol. 34. Basel; Karger 2006: 242-250
  • 5 Ahmed N, Corey M, Forstner G et al.. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.  Gut. 2003;  52 1159-1164
  • 6 Westaby D. Cystic fibrosis: liver disease. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol 34. Basel; Karger 2006: 251-261
  • 7 Knowles M R, Durie P R. What is cystic fibrosis?.  N Engl J Med. 2002;  347 439-442
  • 8 Murphy J L, Wootton S A, Bond S A, Jackson A A. Energy content of stools in healthy controls and patients with cystic fibrosis.  Arch Dis Child. 1991;  66 495-500
  • 9 Bell S C, Shepherd R W. Optimising nutrition in cystic fibrosis.  J Cyst Fibros. 2002;  1 47-50
  • 10 Abbott J, Conway S P, Etherington C et al.. Perceived body image and eating behaviour in young adults with cystic fibrosis and their healthy peers.  J Behav Med. 2000;  23 501-517
  • 11 Duff A JA, Wolfe S P, Dickson C, Conway S P, Brownlee K G. Feeding behaviour problems in children with cystic fibrosis in the UK: prevalence and comparison with healthy controls.  J Pediatr Gastroenterol Nutr. 2003;  36 443-447
  • 12 Poustie V J, Russell J E, Watling R M, Ashby D, Smyth R L. CALICO Trial Collaborative Group . Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial.  BMJ. 2006;  332 632-636
  • 13 Bell S C, Saunders M J, Elborn J S, Shale D J. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis.  Thorax. 1996;  51 126-131
  • 14 Bradley J, McAllister O, Elborn J S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis.  Eur Respir J. 2001;  17 712-715
  • 15 Bell S C, Bowerman A M, Nixon L E, MacDonald I A, Elborn J S, Shale D J. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis.  Eur J Clin Invest. 2000;  30 553-559
  • 16 McCloskey M, Redmond A OB, Pyper S, McCabe C, Westerterp K P, Elborn J S. Total energy expenditure in stable patients with cystic fibrosis.  Clin Nutr. 2001;  20 235-241
  • 17 Courtney J M, Ennis M, Elborn J S. Cytokines and inflammatory mediators in cystic fibrosis.  J Cyst Fibros. 2004;  3 223-231
  • 18 Fried M D, Durie P R, Tsui L C, Corey M, Levison H, Pencharz P B. The cystic fibrosis gene and resting energy expenditure.  J Pediatr. 1991;  119 913-916
  • 19 Fuchs H J, Borowitz D S, Christiansen D H et al.. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.  N Engl J Med. 1994;  331 637-642
  • 20 Saiman L, Marshall B C, Mayer-Hamblett N Macrolide Study Group et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.  JAMA. 2003;  290 1749-1756
  • 21 Hardin D S, Rice J, Ahn C et al.. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition.  J Pediatr. 2005;  146 324-328
  • 22 Boguszewski M C, Kamoi T O, Bento Radominski R et al.. Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis.  Horm Res. 2007;  67 250-256
  • 23 Eubanks V, Koppersmith N, Wooldridge N et al.. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis.  J Pediatr. 2002;  140 439-444
  • 24 Elkin S L, Verdi S, Bord S, Garrahan N J, Hodson M E, Compston J E. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis.  Am J Respir Crit Care Med. 2002;  166 1470-1474
  • 25 Haworth C S, Selby P L, Webb A K et al.. Low bone mineral density in adults with cystic fibrosis.  Thorax. 1999;  54 961-967
  • 26 Rossini M, Del Marco A, Dal Santo F et al.. Prevalence and correlates of vertebral fractures in adults with cystic fibrosis.  Bone. 2004;  35 771-776
  • 27 Bone disease in cystic fibrosis.  Cystic Fibrosis Trust. 2007;  http://www.cftrust.org.uk
  • 28 Conway S P, Morton A M, Oldroyd B et al.. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors.  Thorax. 2000;  55 798-804
  • 29 Haworth C S, Selby P L, Webb A K et al.. Low bone mineral density in adults with cystic fibrosis.  Thorax. 1999;  54 961-967
  • 30 Aris R M, Merkel P A, Bachrach L K et al.. Consensus statement: guide to bone health and disease in cystic fibrosis.  J Clin Endocrinol Metab. 2005;  90 1888-1896
  • 31 Hardin D S, Arumugam R, Seillheimer D K, LeBlanc A, Ellis K J. Normal bone mineral density in cystic fibrosis.  Arch Dis Child. 2001;  84 363-368
  • 32 Ionescu A A, Nixon L S, Evans W D et al.. Bone density, body composition and inflammatory status in cystic fibrosis.  Am J Respir Crit Care Med. 2000;  162 789-794
  • 33 Aris R M, Ontjes D A, Brown S A, Chalermskulrat W, Neuringer I, Lester G E. Carboxylated osteocalcin levels in cystic fibrosis [letter].  Am J Respir Crit Care Med. 2003;  168 1129
  • 34 King S J, Topliss D J, Kotsimbos T et al.. Reduced bone density in cystic fibrosis: ΔF508 mutation is an independent risk factor.  Eur Respir J. 2005;  25 54-61
  • 35 Dif F, Marty C, Baudoin C, de Vernejoul M C, Levi G. Severe osteopenia in CFTR-null mice.  Bone. 2004;  35 595-603
  • 36 Buntain H M, Greer R M, Schluter P J et al.. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study.  Thorax. 2004;  59 149-155
  • 37 Aris R M, Merkel P A, Bachrach L K et al.. Guide to bone health and disease in cystic fibrosis.  J Clin Endocrinol Metab. 2005;  90 1888-1896
  • 38 Aris R M, Stephens A R, Ontjes D A et al.. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis.  Am J Respir Crit Care Med. 2000;  162 1674-1678
  • 39 Haworth C S, Selby P L, Webb A K et al.. Inflammatory related changes in bone mineral content in adults with cystic fibrosis.  Thorax. 2004;  59 613-617
  • 40 Boyle M P, Lechtzin N, Merlo C A et al.. Determination of ideal serum 25-hydroxyvitamin D levels in adults with CF by evaluation of effects on parathyroid hormone levels [abstract].  Pediatr Pulmonol. 2005;  28 353
  • 41 Bonjour J P, Chevalley T, Amman P, Slosman D, Rizzoli R. Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study.  Lancet. 2001;  358 1208-1212
  • 42 Conway S P, Wolfe S P, Brownless K G et al.. Vitamin K status in children with cystic fibrosis and its relationship to bone mineral density and bone turnover.  Pediatrics. 2005;  115 1325-1331
  • 43 McKay H A, Petit M A, Schutz R W, Prior J C, Barr S I, Khan K M. Augmented trochanteric bone mineral density after modified physical education classes: a randomised, school-based exercise intervention study in prepubescent and early pubescent children.  J Pediatr. 2000;  136 156-162
  • 44 Aris R M, Lester G E, Caminiti M et al.. Efficacy of alendronate in adults with cystic fibrosis with low bone density.  Am J Respir Crit Care Med. 2004;  169 77-82
  • 45 Conway S P, Oldroyd B, Morton A, Truscott J G, Peckham D G. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study.  Thorax. 2004;  59 699-703
  • 46 Haworth C S, Selby P L, Adams J E, Mawer E B, Horrocks A M, Webb A K. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.  Thorax. 2001;  56 314-316
  • 47 Elkin S. Arthritis, vasculitis and bone disease. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol 34. Basel; Karger 2006: 270-277
  • 48 Finnegan M J, Hinchcliffe J, Russell-Jones D et al.. Vasculitis complicating cystic fibrosis.  Q J Med. 1989;  72 609-621
  • 49 Zhao M H, Jayne D R, Ardiles L G, Culley F, Hodson M E, Lockwood C M. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.  QJM. 1996;  89 259-265
  • 50 Management of cystic fibrosis diabetes mellitus.  Cystic Fibrosis Trust. 2004;  http://www.cftrust.org.uk
  • 51 Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Geneva; WHO 2006
  • 52 Brennan A L, Geddes D M, Gyi K M, Baker E H. Clinical importance of cystic fibrosis-related diabetes.  J Cyst Fibros. 2004;  3 209-222
  • 53 Stalvey M S, Muller C, Schatz D A et al.. Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury.  Diabetes. 2006;  55 1939-1945
  • 54 Bridges N, Spowart K. Diabetes in cystic fibrosis. In: A Bush, EWFW Alton, JC Davies, U Griesenbach, A Jaffe Cystic Fibrosis in the 21st Century. Progressive Respiratory Research, vol 34. Basel; Karger 2006: 278-283
  • 55 Hardin D S, Leblanc A, Marshall G, Seilheimer D K. Mechanisms of insulin resistance in cystic fibrosis.  Am J Physiol Endocrinol Metab. 2001;  281 E1022-E1028
  • 56 Mueller-Brandes C, Holl R W, Nastoll M, Ballmann M. New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis.  Eur Respir J. 2005;  25 715-717
  • 57 Koch C, Rainisio M, Madessani U Investigators of the European Epidemiologic Registry of Cystic Fibrosis et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis.  Pediatr Pulmonol. 2001;  32 343-350
  • 58 Milla C E, Warwick W J, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline.  Am J Respir Crit Care Med. 2000;  162 891-895
  • 59 Milla C E, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis.  Diabetes Care. 2005;  28 2141-2144
  • 60 Dobson L, Sheldon C D, Hattersley A T. Conventional measures underestimate glycaemia in cystic fibrosis patients.  Diabet Med. 2004;  21 691-696
  • 61 Corbett K, Kellecher S, Rowland M et al.. Cystic fibrosis-associated liver disease: a population-based study.  J Pediatr. 2004;  145 327-332
  • 62 Lamireau T, Monnereau S, Martin S, Marcotte J E, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study.  J Hepatol. 2004;  41 920-925
  • 63 Colombo C, Castellani M R, Balistreri W F, Seregni E, Assaisso M L, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease.  Hepatology. 1992;  15 677-684
  • 64 Sokol R J, Durie P R. Recommendations for management of liver biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group.  J Pediatr Gastroenterol Nutr. 1999;  28 S1-S13
  • 65 Colombo C, Crosignani A, Assaisso M et al.. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.  Hepatology. 1992;  16 924-930
  • 66 Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.  Hepatology. 1998;  27 166-174
  • 67 Cheng K, Ashby D, Smyth R. Ursodeoxycholic acid for cystic fibrosis related liver disease.  Cochrane Database Syst Rev. 2000;  (2) CD00222
  • 68 Beuers U, Spengler U, Kruis W et al.. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a controlled trial.  Hepatology. 1992;  16 707-714
  • 69 Jalan R, Hayes P C. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology.  Gut. 2000;  46 S3-S4 III1-III15
  • 70 Pozler O, Krajina A, Vanicek H et al.. Transjugular intro-hepatic portosystemic shunt in five children with cystic fibrosis: long-term results.  Hepatogastroenterology. 2003;  50 1111-1114
  • 71 De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.  Pediatrics. 2005;  115 e463-e469 , Epub 2005 Mar 16
  • 72 Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis D E. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood.  Chest. 2004;  126 1215-1224
  • 73 Durno C, Corey M, Zielenski J, Tullis E, Tsui L C, Durie P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis.  Gastroenterology. 2002;  123 1857-1864
  • 74 Bishop M D, Freedman S D, Zielenski J et al.. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis.  Hum Genet. 2005;  118 372-381 , Epub 2005 Sep 29
  • 75 Nutritional management of cystic fibrosis. Cystic Fibrosis Trust. http://www.cftrust.org.uk
  • 76 Campbell D C, Tole D M, Doran R ML, Conway S P. Vitamin A deficiency in cystic fibrosis resulting in severe xerophthalmia.  J Hum Nutr Diet. 1998;  11 529-532
  • 77 Back E I, Frindt C, Nohr D et al.. Antioxidant deficiency in cystic fibrosis: when is the right time to take action?.  Am J Clin Nutr. 2004;  80 374-384
  • 78 Oudshoorn J H, Klijn P H, Hofman Z et al.. Dietary supplementation with multiple micronutrients: No beneficial effects in pediatric cystic fibrosis patients.  J Cyst Fibros. 2007;  6 35-40 , Epub 2006 Jun 19
  • 79 Greer R M, Buntain H M, Lewindon P J et al.. Vitamin A levels in patients with CF are influenced by the inflammatory response.  J Cyst Fibros. 2004;  3 143-149
  • 80 Boyle M P, Noschese M L, Watts S L, Davis M E, Stenner S E, Lechtzin N. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis.  Am J Respir Crit Care Med. 2005;  172 212-217
  • 81 Wilson D C, Rashid M, Durie P R et al.. Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination.  J Pediatr. 2001;  138 851-855
  • 82 Nicolaidou P, Stavrinadis I, Loukou I et al.. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis.  Eur J Pediatr. 2006;  165 540-545
  • 83 Feldmann M, Brennan F M, Foxwell B M, Taylor P C, Williams R O, Maini R N. Anti-TNF therapy: where have we got to in 2005?.  J Autoimmun. 2005;  25 26-28 , Epub 2005 Nov 2
  • 84 Antoniu S A. Etanercept for refractory asthma therapy.  Expert Opin Investig Drugs. 2006;  15 1279-1281
  • 85 Marcora S M, Chester K R, Mittal G, Lemmey A B, Maddison P J. Randomised phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis.  Am J Clin Nutr. 2006;  84 1463-1472
  • 86 Tilg H, Kaser A, Moschen A R. How to modulate inflammatory cytokines in liver diseases.  Liver Int. 2006;  26 1029-1039

J Stuart ElbornM.D. 

Respiratory Medicine Group, QUB and Northern Ireland Adult Cystic Fibrosis Centre

City Hospital, Lisburn Rd., Belfast, BT9 7AB, Ireland

Email: stuart.elborn@bch.n-i.nhs.uk

    >